Circassia plays long game with £175m London IPO
UK biotech firm Circassia has not yet launched bookbuilding on its IPO, despite launching almost three weeks ago. The deal was launched after a run of deals in the US, which have since seen rocky aftermarket performance.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts